Politics / Law

EM(E)A updates, structure and URL

01.02.2010

London – The European Medicines Agency (formerly EMEA, now EMA) reported in January that it is adapting its organisational structure to its increasing workload and interactions with patient and consumer organisations. Human pre- and post-authorisation activities have been unified into a single unit, a newly-created unit for patient health protection will be responsible for safety-monitoring of medicines, and a dedicated group for the management of product data and documentation will improve the Agency’s data-management processes. The organisational changes go hand-in-hand with the preparation of a new website to be launched by the end of Q2/2010, as well as a new logo. Additionally, the search is now formally open for the next head of the Agency, which employs more than 600 staff and has a 2010 budget of about EUR198m (2009: EUR194m). Current director Thomas Lönngren will step down at the end of this year. In January, the EMA Board proposed widening the scope of patient and consumer contributions to the Agency. One proposal was to define the conditions where it is meaningful to invite the representatives of various groups to participate in benefit-risk evaluations of medicines, or as observers in meetings of the Pharmacovigilance Working Party to help contribute to the Agency’s safety communications.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/emea-updates-structure-and-url.html

Product of the week

Products

Events

All Events

Current issue

All issues